11 Melanoma Clinical Trials in Houston, NC (2026)

Q: How do I join a clinical trial in Houston?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Houston research site will contact you.

Recruiting Melanoma Studies in Houston

NCT04778449Recruiting

Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma

This study investigates the extent to which lifestyle factors including mental health, social support, diet, and exercise are associated with quality of life and melanoma patient outcomes. Knowledge g...

Houston, NC5,000 participantsM.D. Anderson Cancer Center

View Study Details

NCT03819296Recruiting

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

This trial studies the role of the gut microbiome and effectiveness of a fecal transplant on medication-induced gastrointestinal (GI) complications in patients with melanoma or genitourinary cancer. T...

Houston, NC800 participantsM.D. Anderson Cancer Center

View Study Details

NCT04594187Recruiting

Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma

This phase II trial seeks to determine the role of nodal radiation therapy after sentinel lymph node biopsy (SLNB) for patients with high risk sentinel lymph node positive melanoma who are planned for...

Houston, NC168 participantsM.D. Anderson Cancer Center

View Study Details

NCT07287917Recruiting

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

This study will evaluate the safety, tolerability, and preliminary effectiveness of AMXT 1501 and DFMO when combined with standard treatments for advanced solid tumors. The trial includes two groups: ...

Houston, NC92 participantsAminex Therapeutics, Inc.

View Study Details

NCT06466434Recruiting

Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma

To learn about the possible effects of a prebiotic food-enriched diet (PreFED) targeting the gut microbiome in participants with melanoma who are starting immune checkpoint blockade (ICB) therapy....

Houston, NC75 participantsM.D. Anderson Cancer Center

View Study Details

NCT06545682Recruiting

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

To find a recommended dose of the combination of alpelisib and pembrolizumab that can be given to patients with metastatic breast cancer or melanoma....

Houston, NC50 participantsM.D. Anderson Cancer Center

View Study Details

NCT05546827Recruiting

Preoperative Radiotherapy and Immunotherapy for Sinonasal and Anorectal Mucosal Melanoma

The goal of this clinical research study is to learn if pre-operative radiation therapy after starting immune checkpoint inhibition can help patients with sinonasal or anorectal melanoma have better o...

Houston, NC40 participantsM.D. Anderson Cancer Center

View Study Details

NCT06548789Recruiting

Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED

To Determine the feasibility, compliance and adherence to PreFED intervention in resectable melanoma patients initiating neoadjuvant Ipi/Nivo....

Houston, NC35 participantsM.D. Anderson Cancer Center

View Study Details

NCT05026983Recruiting

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

This phase II trial studies the effects of binimetinib and encorafenib in treating patients with melanoma that has spread to the central nervous system (metastases). Binimetinib and encorafenib may st...

Houston, NC35 participantsM.D. Anderson Cancer Center

View Study Details

NCT05704647Recruiting

Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases

To learn if giving nivolumab in combination with relatlimab can help to control melanoma that has spread to the brain (melanoma with brain metastases). The safety and side effects of the study drug co...

Houston, NC30 participantsM.D. Anderson Cancer Center

View Study Details

NCT06946225Recruiting

ACTengine® IMA203 Combined With mRNA-4203

This purpose of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA203 in combination with different doses of mRNA-4203. The trial includes participants with pre...

Houston, NC15 participantsImmatics US, Inc.

View Study Details

About Melanoma Clinical Trials in Houston

Melanoma is the most serious type of skin cancer, developing from the pigment-producing cells known as melanocytes. While less common than other skin cancers, melanoma is more likely to spread. Immunotherapy and targeted therapy have revolutionized melanoma treatment.

There are currently 11 melanoma clinical trials recruiting participants in Houston, NC. These studies are seeking a combined 6,340 participants. Research is being sponsored by M.D. Anderson Cancer Center, Aminex Therapeutics, Inc., Immatics US, Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.

Melanoma Clinical Trials in Houston — FAQ

Are there melanoma clinical trials in Houston?

Yes, there are 11 melanoma clinical trials currently recruiting in Houston, NC. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Houston?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Houston research site will contact you about next steps.

Are clinical trials in Houston free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Houston studies also compensate for your time and travel.

What melanoma treatments are being tested?

The 11 active trials in Houston are testing new therapies including novel drugs, biologics, and treatment approaches for melanoma.

Data updated July 13, 2026 from ClinicalTrials.gov